What is the current valuation of the US pericarditis market in 2024?

The overall market valuation was $686.1 Million in 2024. Read More

What is the projected market size for the US pericarditis market by 2035?

The projected valuation for 2035 is $1390.41 Million. Read More

What is the expected CAGR for the US pericarditis market during the forecast period 2025 - 2035?

The expected CAGR for the market during this period is 6.63%. Read More

What was the market value for Acute Pericarditis in 2024?

The market value for Acute Pericarditis was between $200.0 Million and $400.0 Million in 2024. Read More

What is the projected market value for Treatment in the US pericarditis market by 2035?

The projected market value for Treatment is expected to reach between $480.0 Million and $970.0 Million by 2035. Read More

How much did the market for Recurrent Pericarditis value in 2024?

The market for Recurrent Pericarditis was valued between $250.0 Million and $500.0 Million in 2024. Read More

What is the expected market value for Hospitals & Clinics in 2035?

The expected market value for Hospitals & Clinics is projected to be between $400.0 Million and $800.0 Million by 2035. Read More

What was the market value for Diagnosis in 2024?

The market value for Diagnosis was between $206.1 Million and $420.41 Million in 2024. Read More

US Pericarditis Market

Q: Which companies are the key players in the US pericarditis market?

Key players include Pfizer Inc, Bristol-Myers Squibb Company, Novartis AG, AstraZeneca PLC, Merck & Co Inc, Sanofi S.A., Gilead Sciences Inc, and Roche Holding AG. Read More

Q: What are the market segments for the US pericarditis market?

The market segments include Acute Pericarditis, Recurrent Pericarditis, Chronic Pericarditis, Diagnosis & Treatment, and End Users. Read More

ID: MRFR/Pharma/18462-HCR 100 Pages Nidhi Mandole Last Updated: September 10, 2026

US Pericarditis Market Research Report By Type (Acute Pericarditis, Recurrent Pericarditis, Chronic Pericarditis), By Diagnosis (Electrocardiogram, Echocardiogram, Computerized Tomography, X-Ray), By Treatment (Medication, Surgical Treatment) and By End User (Hospitals & Clinics, Medical Institutes & Research Laboratories) - Growth & Industry Forecast 2025 To 2035

US Pericarditis Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)6.63%

2024 Market Size$ 686.1 Million

2025 Market Size$ 731.59 Million

2035 Market Size$ 1,390.41 Million

Key Players

Pfizer Inc

Bristol-Myers Squibb Company

Novartis AG

AstraZeneca PLC

Merck & Co Inc

Sanofi S.A.

Trends

Rising Awareness and Education
Advancements in Treatment Options
Integration of Telemedicine

Opportunities

Rising Healthcare Expenditure
Enhanced Diagnostic Techniques
Increasing Incidence of Pericarditis

Summary Table of Contents Segmentation Download PDF

SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
1. 1.1 EXECUTIVE SUMMARY | |
  1. 1.1.1 Market Overview | |
  2. 1.1.2 Key Findings | |
  3. 1.1.3 Market Segmentation | |
  4. 1.1.4 Competitive Landscape | |
  5. 1.1.5 Challenges and Opportunities | |
  6. 1.1.6 Future Outlook 2
SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
1. 2.1 MARKET INTRODUCTION | |
  1. 2.1.1 Definition | |
  2. 2.1.2 Scope of the study | | |
    1. 2.1.2.1 Research Objective | | |
    2. 2.1.2.2 Assumption | | |
    3. 2.1.2.3 Limitations |
2. 2.2 RESEARCH METHODOLOGY | |
  1. 2.2.1 Overview | |
  2. 2.2.2 Data Mining | |
  3. 2.2.3 Secondary Research | |
  4. 2.2.4 Primary Research | | |
    1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
    2. 2.2.4.2 Breakdown of Primary Respondents | |
  5. 2.2.5 Forecasting Model | |
  6. 2.2.6 Market Size Estimation | | |
    1. 2.2.6.1 Bottom-Up Approach | | |
    2. 2.2.6.2 Top-Down Approach | |
  7. 2.2.7 Data Triangulation | |
  8. 2.2.8 Validation 3
SECTION III: QUALITATIVE ANALYSIS |
1. 3.1 MARKET DYNAMICS | |
  1. 3.1.1 Overview | |
  2. 3.1.2 Drivers | |
  3. 3.1.3 Restraints | |
  4. 3.1.4 Opportunities |
2. 3.2 MARKET FACTOR ANALYSIS | |
  1. 3.2.1 Value chain Analysis | |
  2. 3.2.2 Porter's Five Forces Analysis | | |
    1. 3.2.2.1 Bargaining Power of Suppliers | | |
    2. 3.2.2.2 Bargaining Power of Buyers | | |
    3. 3.2.2.3 Threat of New Entrants | | |
    4. 3.2.2.4 Threat of Substitutes | | |
    5. 3.2.2.5 Intensity of Rivalry | |
  3. 3.2.3 COVID-19 Impact Analysis | | |
    1. 3.2.3.1 Market Impact Analysis | | |
    2. 3.2.3.2 Regional Impact | | |
    3. 3.2.3.3 Opportunity and Threat Analysis 4
SECTION IV: QUANTITATIVE ANALYSIS |
1. 4.1 Construction, BY Type (USD Million) | |
  1. 4.1.1 Acute Pericarditis | |
  2. 4.1.2 Recurrent Pericarditis | |
  3. 4.1.3 Chronic Pericarditis |
2. 4.2 Construction, BY Diagnosis & Treatment (USD Million) | |
  1. 4.2.1 Diagnosis | |
  2. 4.2.2 Treatment |
3. 4.3 Construction, BY End User (USD Million) | |
  1. 4.3.1 Hospitals & Clinics | |
  2. 4.3.2 Medical Institutes & Research Laboratories 5
SECTION V: COMPETITIVE ANALYSIS |
1. 5.1 Competitive Landscape | |
  1. 5.1.1 Overview | |
  2. 5.1.2 Competitive Analysis | |
  3. 5.1.3 Market share Analysis | |
  4. 5.1.4 Major Growth Strategy in the Construction | |
  5. 5.1.5 Competitive Benchmarking | |
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Construction | |
  7. 5.1.7 Key developments and growth strategies | | |
    1. 5.1.7.1 New Product Launch/Service Deployment | | |
    2. 5.1.7.2 Merger & Acquisitions | | |
    3. 5.1.7.3 Joint Ventures | |
  8. 5.1.8 Major Players Financial Matrix | | |
    1. 5.1.8.1 Sales and Operating Income | | |
    2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
2. 5.2 Company Profiles | |
  1. 5.2.1 Pfizer Inc (US) | | |
    1. 5.2.1.1 Financial Overview | | |
    2. 5.2.1.2 Products Offered | | |
    3. 5.2.1.3 Key Developments | | |
    4. 5.2.1.4 SWOT Analysis | | |
    5. 5.2.1.5 Key Strategies | |
  2. 5.2.2 Bristol-Myers Squibb Company (US) | | |
    1. 5.2.2.1 Financial Overview | | |
    2. 5.2.2.2 Products Offered | | |
    3. 5.2.2.3 Key Developments | | |
    4. 5.2.2.4 SWOT Analysis | | |
    5. 5.2.2.5 Key Strategies | |
  3. 5.2.3 Novartis AG (CH) | | |
    1. 5.2.3.1 Financial Overview | | |
    2. 5.2.3.2 Products Offered | | |
    3. 5.2.3.3 Key Developments | | |
    4. 5.2.3.4 SWOT Analysis | | |
    5. 5.2.3.5 Key Strategies | |
  4. 5.2.4 AstraZeneca PLC (GB) | | |
    1. 5.2.4.1 Financial Overview | | |
    2. 5.2.4.2 Products Offered | | |
    3. 5.2.4.3 Key Developments | | |
    4. 5.2.4.4 SWOT Analysis | | |
    5. 5.2.4.5 Key Strategies | |
  5. 5.2.5 Merck & Co Inc (US) | | |
    1. 5.2.5.1 Financial Overview | | |
    2. 5.2.5.2 Products Offered | | |
    3. 5.2.5.3 Key Developments | | |
    4. 5.2.5.4 SWOT Analysis | | |
    5. 5.2.5.5 Key Strategies | |
  6. 5.2.6 Sanofi S.A. (FR) | | |
    1. 5.2.6.1 Financial Overview | | |
    2. 5.2.6.2 Products Offered | | |
    3. 5.2.6.3 Key Developments | | |
    4. 5.2.6.4 SWOT Analysis | | |
    5. 5.2.6.5 Key Strategies | |
  7. 5.2.7 Gilead Sciences Inc (US) | | |
    1. 5.2.7.1 Financial Overview | | |
    2. 5.2.7.2 Products Offered | | |
    3. 5.2.7.3 Key Developments | | |
    4. 5.2.7.4 SWOT Analysis | | |
    5. 5.2.7.5 Key Strategies | |
  8. 5.2.8 Roche Holding AG (CH) | | |
    1. 5.2.8.1 Financial Overview | | |
    2. 5.2.8.2 Products Offered | | |
    3. 5.2.8.3 Key Developments | | |
    4. 5.2.8.4 SWOT Analysis | | |
    5. 5.2.8.5 Key Strategies |
3. 5.3 Appendix | |
  1. 5.3.1 References | |
  2. 5.3.2 Related Reports 6 LIST OF FIGURES |
4. 6.1 MARKET SYNOPSIS |
5. 6.2 US MARKET ANALYSIS BY TYPE |
6. 6.3 US MARKET ANALYSIS BY DIAGNOSIS & TREATMENT |
7. 6.4 US MARKET ANALYSIS BY END USER |
8. 6.5 KEY BUYING CRITERIA OF CONSTRUCTION |
9. 6.6 RESEARCH PROCESS OF MRFR |
10. 6.7 DRO ANALYSIS OF CONSTRUCTION |
11. 6.8 DRIVERS IMPACT ANALYSIS: CONSTRUCTION |
12. 6.9 RESTRAINTS IMPACT ANALYSIS: CONSTRUCTION |
13. 6.10 SUPPLY / VALUE CHAIN: CONSTRUCTION |
14. 6.11 CONSTRUCTION, BY TYPE, 2024 (% SHARE) |
15. 6.12 CONSTRUCTION, BY TYPE, 2024 TO 2035 (USD Million) |
16. 6.13 CONSTRUCTION, BY DIAGNOSIS & TREATMENT, 2024 (% SHARE) |
17. 6.14 CONSTRUCTION, BY DIAGNOSIS & TREATMENT, 2024 TO 2035 (USD Million) |
18. 6.15 CONSTRUCTION, BY END USER, 2024 (% SHARE) |
19. 6.16 CONSTRUCTION, BY END USER, 2024 TO 2035 (USD Million) |
20. 6.17 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
21. 7.1 LIST OF ASSUMPTIONS | |
  1. 7.1.1 |
22. 7.2 US MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.2.1 BY TYPE, 2025-2035 (USD Million) | |
  2. 7.2.2 BY DIAGNOSIS & TREATMENT, 2025-2035 (USD Million) | |
  3. 7.2.3 BY END USER, 2025-2035 (USD Million) |
23. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
  1. 7.3.1 |
24. 7.4 ACQUISITION/PARTNERSHIP | |

Certified Researchers

Enquiry

Customize Report

US Pericarditis Market Segmentation

US Pericarditis Market By Type (USD Million, 2025-2035)

Acute Pericarditis
Recurrent Pericarditis
Chronic Pericarditis

US Pericarditis Market By Diagnosis & Treatment (USD Million, 2025-2035)

Diagnosis
Treatment

US Pericarditis Market By End User (USD Million, 2025-2035)

Hospitals & Clinics
Medical Institutes & Research Laboratories

Certified Researchers

Enquiry

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”

Guilherme Gomes Martins Product Management Director

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”